File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An audit of antiasthmatic drug inhalation technique and understanding

TitleAn audit of antiasthmatic drug inhalation technique and understanding
Authors
Issue Date1993
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/02770903.asp
Citation
Journal Of Asthma, 1993, v. 30 n. 4, p. 263-269 How to Cite?
AbstractInhaled rather than oral antiasthmatic therapy is accepted as more advantageous but depends on patient technique and understanding. In 74 asthmatic outpatients, technique using metered-dose inhaler (MDI) was poor; in 56 patients inhaling β-agonist, the mean peak expiratory flow rate (PEFR) increase was only 15 L/min (6%) greater than in 16 controls, p < 0.05, 95% confidence intervals 2-27 L/min or 2-11%. Tilting the head back and actuation 'stopping' inspiration produced the least favorable PEFR responses; taken together, regression analysis yielded a statistically significant negative correlation with absolute or percentage PEFR change (R2 = 0.15; p < 0.02). Patients were unclear about which drugs to inhale as required or regularly. Among 19 patients reassessed inhaling β-agonist, only 6 had baseline PEFR values with in 10% of each other during both assessments. In the latter, the mean postinhalation PEFR increase was 36 L/min (or 13%) greater than the corresponding increase (or % change) at first assessment, p = 0.05 (0.08), 95% confidence intervals 0-73 L/min (-2 to 29%). Thus, MDI users should avoid tilting the head back, actuation stopping inhalation, and be more aware of prophylactic (steroid) versus symptomatic (β-agonist) treatment.
Persistent Identifierhttp://hdl.handle.net/10722/161980
ISSN
2015 Impact Factor: 1.854
2015 SCImago Journal Rankings: 0.762
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKumana, CRen_US
dc.contributor.authorSo, SYen_US
dc.contributor.authorLauder, IJen_US
dc.contributor.authorIp, MSMen_US
dc.contributor.authorLam, WKen_US
dc.contributor.authorKou, Men_US
dc.date.accessioned2012-09-05T05:16:26Z-
dc.date.available2012-09-05T05:16:26Z-
dc.date.issued1993en_US
dc.identifier.citationJournal Of Asthma, 1993, v. 30 n. 4, p. 263-269en_US
dc.identifier.issn0277-0903en_US
dc.identifier.urihttp://hdl.handle.net/10722/161980-
dc.description.abstractInhaled rather than oral antiasthmatic therapy is accepted as more advantageous but depends on patient technique and understanding. In 74 asthmatic outpatients, technique using metered-dose inhaler (MDI) was poor; in 56 patients inhaling β-agonist, the mean peak expiratory flow rate (PEFR) increase was only 15 L/min (6%) greater than in 16 controls, p < 0.05, 95% confidence intervals 2-27 L/min or 2-11%. Tilting the head back and actuation 'stopping' inspiration produced the least favorable PEFR responses; taken together, regression analysis yielded a statistically significant negative correlation with absolute or percentage PEFR change (R2 = 0.15; p < 0.02). Patients were unclear about which drugs to inhale as required or regularly. Among 19 patients reassessed inhaling β-agonist, only 6 had baseline PEFR values with in 10% of each other during both assessments. In the latter, the mean postinhalation PEFR increase was 36 L/min (or 13%) greater than the corresponding increase (or % change) at first assessment, p = 0.05 (0.08), 95% confidence intervals 0-73 L/min (-2 to 29%). Thus, MDI users should avoid tilting the head back, actuation stopping inhalation, and be more aware of prophylactic (steroid) versus symptomatic (β-agonist) treatment.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/02770903.aspen_US
dc.relation.ispartofJournal of Asthmaen_US
dc.subject.meshAdministration, Inhalationen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdrenergic Beta-Agonists - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAsthma - Drug Therapy - Physiopathologyen_US
dc.subject.meshChilden_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNebulizers And Vaporizersen_US
dc.subject.meshPeak Expiratory Flow Rateen_US
dc.subject.meshSelf Administrationen_US
dc.titleAn audit of antiasthmatic drug inhalation technique and understandingen_US
dc.typeArticleen_US
dc.identifier.emailIp, MSM:msmip@hku.hken_US
dc.identifier.authorityIp, MSM=rp00347en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3109/02770909309054526-
dc.identifier.pmid8101183en_US
dc.identifier.scopuseid_2-s2.0-0027295969en_US
dc.identifier.volume30en_US
dc.identifier.issue4en_US
dc.identifier.spage263en_US
dc.identifier.epage269en_US
dc.identifier.isiWOS:A1993LP68100004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridKumana, CR=7005112381en_US
dc.identifier.scopusauthoridSo, SY=7102397816en_US
dc.identifier.scopusauthoridLauder, IJ=35564928000en_US
dc.identifier.scopusauthoridIp, MSM=7102423259en_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridKou, M=7004545950en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats